Concise Review for Primary-Care Physicians
|
|
- Arron Stafford
- 5 years ago
- Views:
Transcription
1 Concise Review for Primary-Care Physicians Acute Porphyrias: Diagnosis and Management AYALEW TEFFERI, M.D., JOSEPH P. COLGAN, M.D., AND LAWRENCE A. SOLBERG, JR., M.D. To summarize recent information about acute porphyrias and to provide clinicians with a practical diagnostic and management approach, we reviewed the pertinent literature and our clinical experience. The acute porphyrias are characterized by recurrent attacks of abdominal pain with or without additional manifestations of autonomie dysfunction or neuropsychiatrie symptoms. On the basis of the potential of these disorders to affect the skin, they are further subdivided into neuroporphyrias and neurocutaneous porphyrias. During acute attacks, acute porphyria is always associated with increased levels of urinary porphyrin precursors. Between attacks, patients with neurocutaneous porphyrias may have normal urinary porphyrins; therefore, stool porphyrins, which are invariably increased, are the most helpful. Latent disease can be detected by the measurement of either urinary and stool porphyrins or cellular enzyme activity. Specific intravenous therapy with hematin has resulted in biochemical remissions, but its clinical benefit remains controversial. Measurement of urinary and stool porphyrins or porphyrin precursors is critical for the diagnosis of clinically overt acute porphyria. Enzyme assays are helpful in supporting the diagnosis but are best used to identify family members with latent disease. Preventive measures and supportive therapy are the mainstays of current management of patients with porphyria. (Mayo Clin Proc 1994; 69: ) AIP = acute intermittent porphyria; ALA = δ-aminolevulinic acid; HCP = hereditary coproporphyria; PBG = porphobilinogen; PP = plumboporphyria; VP = variegate porphyria The porphyrias, which are inherited enzyme disorders, affect the biosynthesis of heme and result in accumulation of excessive porphyrins or porphyrin precursors. Most of these disorders are inherited as autosomal dominant traits; however, disease penetrance is low, and most carriers of the genetic abnormality have latent porphyria and are clinically asymptomatic.1 Patients who are carriers of the genetic defect may be identified by measuring the defective enzyme activity in blood cells or by quantifying porphyrins in urine or stool specimens. Clinicians should be aware that carriers of the genetic defect do not necessarily have clinically overt disease; in patients with latent porphyria, substantial excretion of porphyrins or decreased cellular enzyme activity may be noted. Symptoms and signs of porphyria, however, are always associated with increased excretion of porphyrins or porphyrin precursors. Therefore, even in the presence of reduced cellular enzyme activity, a disease manifestation cannot be attributed to porphyria unless urine or stool porphyrins are concurrently increased. From the Division of Hematology and Internal Medicine (A.T., J.P.C.), Mayo Clinic Rochester, Rochester, Minnesota; and Division of Hematology/Oncology (L.A.S.), Mayo Clinic Jacksonville, Jacksonville, Florida. Address reprint requests to Dr. Ayalew Tefferi, Division of Hematology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN HEME BIOSYNTHESIS The porphyrins are molecules produced along the heme biosynthetic pathway. Heme, which consists of protoporphyrin IX (the finished porphyrin product) and iron, is a functionally important component of hemoglobin, myoglobin, and heme-requiring enzymes such as the cytochrome P-450 oxidase system. Consequently, protoporphyrin biosynthesis is most pronounced in erythrocytes and hepatic cells. Protoporphyrin biosynthesis begins in the mitochondria, where glycine and succinylcoenzyme A condense to form δ- aminolevulinic acid (ALA) (catalyzed by ALA synthase). In the liver, this is the rate-limiting reaction of heme synthesis, and ALA synthase is negatively regulated by heme; in contrast, erythroid-specific ALA synthase is neither rate-limiting nor negatively regulated by heme. The subsequent steps in heme biosynthesis occur in the cytoplasm. Two ALA molecules condense to form the monopyrrole ring, porphobilinogen (PBG) (catalyzed by ALA dehydratase). Four molecules of PBG join to form an intermediary linear tetrapyrrole product called hydroxymethylbilane (catalyzed by PBG deaminase). Hydroxymethylbilane cyclizes into either uroporphyrinogen I (a spontaneous nonenzymatic reaction) or uroporphyrinogen III (catalyzed by uroporphyrinogen III synthase). Uroporphyrinogen III is converted to coproporphyrinogen III (catalyzed by uroporphyrinogen decarboxylase). Mayo Clin Proc 1994; 69: Mayo Foundation for Medical Education and Research
2 992 ACUTE PORPHYRIAS Mayo Clin Proc, October 1994, Vol 69 Coproporphyrinogen III reenters the mitochondria and is converted to protoporphyrinogen IX (catalyzed by coproporphyrinogen oxidase). Protoporphyrinogen IX is then oxidized to protoporphyrin IX (catalyzed by protoporphyrinogen oxidase). The final step is the production of heme by the insertion of an iron atom in the center of the protoporphyrin IX ring (catalyzed by ferrochelatase). TYPES OF PORPHYRIAS An enzymatic defect, usually inherited, in any of the aforementioned biosynthetic steps causes excessive accumulation of the substrate porphyrin molecule and thus porphyria. An association exists between the particular disease manifestations and the type of porphyrins accumulated. In clinically overt acute porphyria, the excess is in the early precursor molecules (ALA and PBG), and affected patients will have neurologic manifestations (abdominal pain, vomiting, constipation, seizures, psychosis, peripheral neuropathy, autonomie dysfunction, retention of fluids, tachycardia, hypertension, and sweating). If the excessive porphyrins are the distal substrates (uroporphyrins, coproporphyrins, or protoporphyrins), cutaneous manifestations (such as photosensitivity, skin fragility, facial hypertrichosis, and hyperpigmentation) will be noted. With an excess of both early and distal porphyrin molecules, the manifestations will include both neurologic and cutaneous signs and symptoms. Thus, the porphyrias can be classified by their potential to involve the nervous system, the skin, or both. The cutaneous porphyrias, which produce prominent skin manifestations, are porphyria cutanea tarda, congenital erythropoietic porphyria, and erythropoietic protoporphyria. The neuroporphyrias acute intermittent porphyria (AIP) and plumboporphyria (PP) cause purely neurologic manifestations. The neurocutaneous porphyrias, in which both the skin and the nervous system may be involved, are hereditary coproporphyria (HCP) and variegate porphyria (VP). Although most porphyrias are autosomal dominant, notable exceptions are PP and congenital erythropoietic porphyria, which are autosomal recessive. In addition, homozygote variants of HCP and porphyria cutanea tarda have been described. The acute porphyrias, a group of porphyric disorders characterized by acute and recurrent neurologic attacks, include both the neuroporphyrias (AIP and PP) and the neurocutaneous porphyrias (HCP and VP). Although the pathogenesis of the associated manifestations is unknown, increased urinary excretion of ALA, PBG, or both seems to be an invariable finding. The accumulation of these early porphyrin precursors is caused by decreased activity of PBG deaminase or ALA dehydratase. In the neuroporphyrias, the decreased activity results from a hereditary enzyme deficiency. In the neurocutaneous porphyrias, the decreased PBG deaminase activity is attributable to allosteric inhibition, by excess protoporphyrinogens and coproporphyrinogens, of PBG deaminase. 2 Neuroporphyrias. In patients with AIP, the partially defective enzyme is PBG deaminase, and the substrate molecule (PBG) and its immediate precursor (ALA) accumulate. Exogenous (alcohol, drugs, and hormones) or endogenous (infection and starvation) stimuli that induce ALA synthase and result in overproduction of ALA can precipitate acute attacks, whereas glucose prevents induction of the enzyme and may ameliorate symptoms ("glucose effect") The urinary excretion of these precursors is always very high during attacks and lower but not normal between attacks. 3 4 Of importance, in most patients with such a defective gene, the disease does not manifest (that is, they have latent porphyria). 1 5 These patients do have biochemical evidence of disease (decreased PBG deaminase activity and normal or increased urinary porphyrins or porphyrin precursors). When clinical disease is present, the manifestations include recurrent autonomie dysfunction, which is expressed as abdominal pain, nausea or vomiting, constipation, tachycardia, and hypertension. Unusual manifestations include the syndrome of inappropriate production of antidiuretic hormone, fever, leukocytosis, paresis of the extremities, and peripheral edema. The diagnosis of the second type of neuroporphyria PP (ALA dehydratase deficiency) is suggested by a pronounced increase in urinary ALA and decreased erythrocyte ALA dehydratase activity. This disorder is rare (only four cases have been reported thus far), 6 and the biochemical manifestations are similar to those attributable to lead intoxication (lead inhibits ALA dehydratase) or hereditary tyrosinemia (succinylacetone excess inhibits ALA dehydratase). Neurocutaneous Porphyrias. Two types of porphyria HCP and VP demonstrate both cutaneous and neurologic manifestations. In both these disorders, the terminal inadequacy of heme synthesis deprives the negative feedback with ALA synthase and results in overproduction of precursors; thus, neurologic symptoms and laboratory findings consistent with AIP eventuate. Unlike patients with AIP, however, those with clinically manifested HCP or VP may have normal urinary PBG and ALA levels during asymptomatic periods. In these patients, stool porphyrins are almost always increased. In VP, a deficiency of proto-oxidase activity leads to accumulation of protoporphyrinogen and protoporphyrin (produced by nonenzymatic oxidation of protoporphyrinogen) in bile and feces. VP can coexist with porphyria cutanea tarda (dual porphyria) or AIP (ehester porphyria). The diagnosis is suggested by persistent increases in fecal
3 Mayo Clin Proc, October 1994, Vol 69 ACUTE PORPHYRIAS 993 protoporphyrins and coproporphyrins and increases in urinary ALA and PBG during acute attacks. In HCP, the defective enzyme is copro-oxidase, and coproporphyrin accumulates primarily in the stool but also in the urine. Copro-oxidase levels are typically 50% of normal and may be as low as 2% in the rare homozygous condition. A variant of homozygous HCP (harderoporphyria) is characterized by increased excretion of harderoporphyrins in the stool. DIAGNOSIS Clinical In patients with unexplained recurrent abdominal pain or recurrent sensorimotor neuropathy with or without associated psychiatric or other neurologic manifestations, the diagnosis of neuroporphyria (AIP or PP) or of neurocutaneous porphyria (HCP or VP) should be considered. The acute attacks are transient but can persist for several days. Therefore, brief episodes (with a duration of less than 1 day) or prolonged and nontransient symptoms are unlikely to be porphyria. Neurologic manifestations can sometimes mimic Guillain-Barré syndrome. Results of analysis of cerebrospinal fluid, however, are usually normal. Useful historical facts include family history, relationship of symptoms to intake of alcohol or drugs, history of photosensitivity, and age at occurrence of initial manifestations. The dominantly inherited variants usually manifest after puberty and earlier in female than male patients. 4 A history of discoloration of the urine is also useful information. Urine that contains large amounts of PBG will darken on standing because of the auto-oxidative conversion of PBG into porphobilin. In contrast, the presence of excessive porphyrins causes red discoloration of the urine. Although skin involvement- is suggestive of the diagnosis of neurocutaneous porphyria, this finding is not always present. 7 8 Laboratory. The laboratory diagnosis of the porphyrias depends primarily on the measurement of porphyrins or their precursors in urine or stool specimens. Remembering that porphyrin intermediates in the first half of the heme biosynthetic pathway (PBG, ALA, and uroporphyrin) are water soluble and fat insoluble is useful. Thus, excessive excretions should be sought in the urine and not in the stool. In contrast, the porphyrin intermediates in the terminal half of the biosynthetic pathway (coproporphyrin and protoporphyrin) are fat soluble and are excreted, through the bile, in the stool. Because coproporphyrin retains some water solubility, it is also excreted in the urine. The second-line test in the evaluation of porphyrias is the measurement of enzyme activity in erythrocytes (when the enzymes involved are cytoplasmic) or nucleated cells such as lymphocytes (when the enzymes involved are in the mitochondria). As previously mentioned, the demonstration of decreased cellular enzyme activity proves the presence of the genetic defect but does not necessarily indicate that the symptoms and signs in a specific patient are attributable to porphyria. For implication of porphyria as the cause of observed neurologic symptoms, urinary ALA or PBG (or both) must be concurrently increased. The enzyme assays are best used for identifying asymptomatic family members whose quantitative porphyrin excretions may be normal. Because acute attacks of porphyria are always associated with substantial increases in ALA, PBG, or both, the essential diagnostic finding is values for these porphyrin intermediates during acute attacks that are more than twice the normal levels. Otherwise, the patient's symptoms cannot be attributed to neuroporphyria or neurocutaneous porphyria. Between attacks, the levels remain abnormal in neuroporphyria but may decline to the normal range in neurocutaneous porphyria For detection of increased levels of PBG, two qualitative screening tests are available the Watson-Schwartz test and the Hoesch test. These studies are based on formation of red pigment when PBG in the urine reacts with Ehrlich's reagent in an acidified solution. These tests, however, are not totally specific, and because of their dependence on high PBG concentrations, they usually yield negative results between attacks. 7 Therefore, quantitative tests should always be done. Methods used to distinguish and quantify urinary and stool porphyrins include high-performance liquid chromatography, solvent extraction, and thin-layer chromatography. Quantitative measurements of PBG are based on ionexchange chromatography. Prominently increased ALA suggests PP, and the diagnosis is supported by the demonstration of decreased ALA dehydratase activity in erythrocytes. This neuroporphyria is also associated with increased urinary coproporphyrin. In AIP, urinary PBG (and occasionally ALA) is increased; the demonstration of diminished erythrocyte PBG deaminase activity strengthens the diagnosis. Because the enzymatic defect may affect only hepatic cells, the finding of normal erythrocyte PBG deaminase activity does not exclude AIP. 1 9 In both neuroporphyrias (AIP and PP), the stool porphyrins are normal. In contrast, stool porphyrins are always increased in neurocutaneous porphyria (both during and between attacks). 7 8 In VP, the preponderant stool porphyrin is protoporphyrin, but coproporphyrin is also increased. 7 HCP is characterized by massive fecal excretion of coproporphyrin and only traces of protoporphyrin. 8 The urinary porphyrin profile (excluding porphyrin precursors) is seldom useful for either diagnosis of or distinction among the acute porphyrias. In AIP, uroporphyrin may be increased because of nonenzymatic polymerization of
4 994 ACUTE PORPHYRIAS Mayo Clin Proc, October 1994, Vol 69 PBG into uroporphyrin. Although substantial coproporphyrinuria is consistent with HCP, this finding lacks specificity, and levels may be normal between attacks. In VP, porphyrin excretion is variable and, similar to HCP, may not be increased during remission. Increases in urinary porphyrins have been noted in several nonporphyric disorders, including lead poisoning (coproporphyrinuria and ALA excretion), liver disease (coproporphyrinuria and uroporphyrinuria), and chronic renal failure during hemodialysis (uroporphyrinuria). In these disorders, stool porphyrins are usually normal. MANAGEMENT The first step for managing the acute porphyrias is confirming the diagnosis. In all affected patients, 24-hour measurements of urinary and stool porphyrins should be done during acute attacks. Between attacks, evaluation should always include measurement of stool porphyrins. As emphasized earlier, the demonstration of decreased cellular enzyme activity, by itself, is insufficient evidence for implication of porphyria as the cause of symptoms. Once the diagnosis has been confirmed, the next step is to ensure appropriate family screening and family counseling. Family members who have no biochemical and enzymatic evidence of disease should be reassured that both they and their offspring have a minimal risk for development of the disease. In contrast, in family members with either latent or overt disease, a 50% possibility exists for occurrence of the genetic defect in their offspring. The risk of subsequent occurrence of acute attacks in patients with latent porphyria is low (less than 10%). 3 Therefore, we do not recommend overzealous restriction of possible "porphyrogenic factors" in family members with latent porphyria. Prevention. The management of specific patients with clinically overt porphyria should begin with a discussion of preventive measures. The patient should wear a warning bracelet and carry a list of medications considered safe and unsafe in porphyria. Precipitation of acute attacks has been associated with starvation, dehydration, infection, menstrual cycles, consumption of alcohol, and administration of several medications. 3 4 Therefore, maintenance of adequate intake of carbohydrates and fluids and avoidance of porphyrogenic drugs are advisable. Most drugs considered unsafe, however, have been implicated on the basis of theoretical risks because of their potential to induce ALA synthase or the cytochrome P-450 system. Few systematic clinical studies have evaluated the actual risks associated with porphyrogenic drugs The evidence incriminating barbiturates, sulfonamides, and excessive use of alcohol is sufficiently strong to recommend strict avoidance of these factors The overall clinical risk associated with other drugs is not well established; the best approach might be careful individualized assessment rather than indiscriminate restrictions. 3 In general, pregnancy does not seem to impose a major risk of precipitating acute attacks and should not be contraindicated in patients with acute porphyria. 3 4 Similarly, despite the high frequency of cyclic symptoms in menstruating women, the use of oral contraceptive pills or other sex hormone preparations is seldom associated with symptoms of porphyria and may be allowed under supervision. 3 Likewise, surgical procedures with use of local or general anesthesia are uncommonly associated with symptoms of porphyria. 3 Treatment of Acute Attacks. During acute attacks of porphyria, the initial step is to identify and address the possible precipitating factor, including review of medications, treatment of active infections, and maintenance of adequate intake of carbohydrates (more than 400 g/day either orally or intravenously as a 10% dextrose solution) and fluids (more than 2 L/day). During fluid resuscitation, the serum sodium level should be monitored to guard against the presence of the syndrome of inappropriate production of antidiuretic hormone, an uncommon complication of acute porphyria. After implementation of the foregoing supportive measures, the second step is to manage particular symptoms and signs of the disease. Pain may be controlled adequately by the use of opiates (morphine, 5 to 10 mg administered intravenously or intramuscularly every 4 hours, or immediaterelease morphine tablets, 10 to 30 mg given orally every 4 hours). Anxiety, agitation, and psychotic symptoms may be managed by the use of phenothiazines (chlorpromazine hydrochloride, 25 to 50 mg administered orally or intramuscularly four times a day). If hypertension and tachycardia need to be treated, ß-blocker therapy (orally administered propranolol, 20 to 40 mg four times a day) may be used. Diazepam (5 to 10 mg intravenously) has been used safely and effectively in patients with seizures. During initiation of therapy with all the aforementioned drugs, the blood pressure and pulse should be monitored closely. Specific intravenous therapy with hematin (Panhematin, 4 mg/kg given every 12 hours for 3 days) has produced biochemical remissions Randomized studies, however, have not shown clinical benefits Similarly, the use of tin protoporphyrin (an inhibitor of heme oxygenase) in combination with hematin has prolonged the biochemical remission induced by hematin, but the clinical course was unaffected. 12 Side effects of hematin include venous irritation and coagulopathy. Biochemical and possibly clinical remission with cimetidine (800 mg/day) has been reported in a patient with AIP. 13 Finally, analogues of luteinizing hormone releasing hormone 14 or oral contraceptives 3 may benefit patients with symptoms related to the menstrual cycle.
5 Mayo Clin Proc, October 1994, Vol 69 ACUTE PORPHYRIAS 995 REFERENCES 1. Pierach CA, Weimer MK, Cardinal RA, Bossenmaier IC, Bloomer JR. Red blood cell porphobilinogen deaminase in the evaluation of acute intermittent porphyria. JAMA 1987; 257: Meissner P, Adams P, Kirsch R. Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen: a possible mechanism for the acute attack of variegate porphyria. J Clin Invest 1993;91: Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992;71: Stein JA, Tschudy DP. Acute intermittent porphyria: a clinical and biochemical study of 46 patients. Medicine 1970;49: Lamon JM, Frykholm BC, Tschudy DP. Family evaluations in acute intermittent porphyria using red cell uroporphyrinogen I synthetase. J Med Genet 1979; 16: Hassoun A, Verstraeten L, Mercelis R, Martin JJ. Biochemical diagnosis of an hereditary aminolaevulinate dehydratase deficiency in a 63-year-old man. J Clin Chem Clin Biochem 1989; 27: Eales L, Levey MJ, Sweeney GD. The place of screening tests and quantitative investigations in the diagnosis of the porphyrias, with particular reference to variegate and symptomatic porphyria. SAfrMedJ 1966;40: With TK. Hereditary coproporphyria and variegate porphyria in Denmark. Dan Med Bull 1983;30: Mustajoki P, Tenhunen R. Variant of acute intermittent porphyria with normal erythrocyte uroporphyrinogen- I-synthase activity. Eur J Clin Invest 1985; 15: Saksena HC, Panwar RB, Rajvanshi P, Sabir M, Suri M. Alcohol and Indian porphyries. Postgrad Med J 1991; 67: Herrick AL, McColl KE, Moore ME, Cook A, Goldberg A. Controlled trial of haem arginate in acute hepatic porphyria. Lancet 1989; 1: Dover SB, Moore MR, Fitzsimmons EJ, Graham A, McColl KE. Tin protoporphyrin prolongs the biochemical remission produced by heme arginate in acute hepatic porphyria. Gastroenterology 1993; 105: Baccino E, Lan Cheong Wah LS, Bressollette L, Mottier D. Cimetidine in the treatment of acute intermittent porphyria [letter]. JAMA 1989; 262: Anderson KE, Spitz IM, Sassa S, Bardin CW, Kappas A. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormonereleasing hormone. N Engl J Med 1984; 311: Questions About Acute Porphyrias (See article, pages 991 to 995) Note: One or more answers may be correct. 1. Abdominal pain or neurologic symptoms can be attributed to acute porphyria only if: a. A family history of porphyria is present b. Stool porphyrins are increased c. Porphyrin precursors in the urine are increased d. Enzyme activity in erythrocytes is decreased e. Uroporphyrin or coproporphyrin in the urine is increased 2. Increased protoporphyrin in the stool is consistent with: a. Acute intermittent porphyria b. Hereditary coproporphyria c. Liver disease d. Variegate porphyria e. Lead intoxication 3. Which of the following is not strongly associated with precipitation of attacks of acute porphyria: a. Excessive use of alcohol b. Pregnancy c. Starvation d. Barbiturates e. Sulfonamides 4. The presence of decreased porphobilinogen deaminase activity in erythrocytes suggests: a. Overt acute porphyria b. Plumboporphyria c. Latent acute intermittent porphyria d. Hereditary coproporphyria e. Lead intoxication 5. Which of the following is controversial in the management of acute porphyria: a. The use of hematin b. Appropriate hydration and nutrition c. Infusion of glucose d. Avoidance of porphyrinogenic medications e. Avoidance of excessive use of alcohol Correct answers: νς Ό-ρ 'q- 'fi 'D\
PORPHYRINS AND PORPHYRIN DISORDERS
1 SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY AND MOLECULAR BIOLOGY ` CLINICAL BIOCHEMISTRY FOR BMLT 3 & BDS 4 PORPHYRINS AND PORPHYRIN DISORDERS
More informationClinical diagnosis? AIP (Acute Intermittent Porphyria)
Case 1 18 yo woman came to ER with a 5-day history of severe abdominal pain Localized, intermittent, sharp, epigastric and periumbilical pain associated with mild nausea but no vomiting for the past 6
More informationDr sadeghi, MD Assistant professor of gastroenterology and hepatology
Dr sadeghi, MD Assistant professor of gastroenterology and hepatology Acute intermittent porphyria is estimated to affect about one in 75 000 people in European countries, apart from in northern Sweden,
More informationDirectorate of Laboratory Medicine Blood Sciences Page 1 of 7 BS-CTG-Biochem-25 Revision Version: 1
Blood Sciences Page 1 of 7 BS-CTG-Biochem-25 Revision Version: 1 SELECTING TESTS FOR THE INVESTIGATION OF THE PORPHYRIAS 1. INTRODUCTION The s are a group of disorders of haem synthesis that can present
More informationالفريق االكاديمي الطبي HLS/ Biochemistry Sheet Porphyrin and Heme metabolism By: Shatha Khtoum
الفريق االكاديمي الطبي HLS/ Biochemistry Sheet Porphyrin and Heme metabolism By: Shatha Khtoum اا Today we will take about heme metabolism: -Heme is iron (Fe +2 ) with 4 pyrrole rings. -Its function it
More informationIron deficiency anemia and porphyrias
Iron deficiency anemia and porphyrias Fleur Wolff¹, Frédéric Cotton¹, Axelle Gilles² ¹Department of clinical chemistry, Hôpital Erasme, ULB ²Department of hematology, Hôpital Erasme, ULB BHS, November
More informationPorphyrias. Thomas A. Kruzel, N D
Porphyrias Thomas A. Kruzel, N D Until recently, cases of porphyrias have been considered rare. It has only been within the past decade or so that an increasing number of patients have been diagnosed with
More informationThe acute porphyrias are well-defined genetic disorders
Review Recommendations for the Diagnosis and Treatment of the Acute Porphyrias Karl E. Anderson, MD; Joseph R. Bloomer, MD; Herbert L. Bonkovsky, MD; James P. Kushner, MD; Claus A. Pierach, MD; Neville
More informationnumber Done by Corrected by Doctor Diala
number 36 Done by Baraa Ayed Corrected by Moath Darweesh Doctor Diala 1 P a g e Today we are going to cover these concepts: Porphyrin structure Biosynthesis of Heme Regulation of heme synthesis A clinical
More informationAcute Porphyria. Penelope Stein Haematological Medicine, King s College Hospital, London
Acute Porphyria Penelope Stein Haematological Medicine, King s College Hospital, London Why is acute porphyria important? Easy to miss - rare, non-specific presentation Severe attacks may be life-threatening
More informationDOWNLOAD PDF DIAGNOSIS AND THERAPY OF PORPHYRIAS AND LEAD INTOXICATION
Chapter 1 : Porphyria - Wikipedia Diagnosis and Therapy of Porphyrias and Lead Intoxication and millions of other books are available for Amazon Kindle. Learn more Enter your mobile number or email address
More informationBIOCHEMISTRY LECTURE BY OJEMEKELE O. BLOOD CHEMISTRY; BLOOD AS A TISSUE AND PORPHYRINS
BIOCHEMISTRY LECTURE BY OJEMEKELE O. BLOOD CHEMISTRY; BLOOD AS A TISSUE AND PORPHYRINS BLOOD AS A TISSUE Blood is a liquid connective tissue The total blood volume makes up about 6-8 percent of the body
More informationVariegate porphyria: an unusual cause of skin blistering
H.K. Dermatol. Venereol. Bull. (2003) 11, 20-24 Case Report Variegate porphyria: an unusual cause of skin blistering Variegate porphyria (VP) is an autosomal dominant disorder caused by a partial deficiency
More informationtherapy and with normal erythrocyte porphobilinogen
Br. J. clin. Pharmac. (1989), 27, 491-497 Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity A. L. HERRICK, K. E. L. McCOLL,
More informationDoaa Kotkot. Somaya Alkiswani. Nayef
6 Doaa Kotkot Somaya Alkiswani Nayef Heme Synthesis In the previous lecture we talked about heme synthesis and we said that the rate limiting step is the condensation of Glycine + Succinyl CoA to produce
More informationACUTE PORPHYRIAS: EMERGENCY ROOM RECOMMENDATIONS
ACUTE PORPHYRIAS: EMERGENCY ROOM RECOMMENDATIONS Neville R Pimstone MD, PhD Gastroenterology/Hepatology, Head Liver Diseases Greater West Los Angeles Veterans Affairs, and Professor Emeritus UC Davis Karl
More informationPORPHYRIAS (Vampires and Crazy Kings)
PORPHYRIAS (Vampires and Crazy Kings) Urs A. Meyer Biozentrum of the University of Basel CH-4056 Basel, Switzerland www.biozentrum.unibas.ch/meyer.html Falk Symposium No.156, Genetics in Liver Diseases
More informationClinical indications for the investigation of porphyria: case examples and evolving laboratory approaches to its diagnosis in New Zealand
Vol 118 No 1222 ISSN 1175 8716 Clinical indications for the investigation of porphyria: case examples and evolving laboratory approaches to its diagnosis in New Zealand Christiaan Sies, Christopher Florkowski,
More informationResearch Article Clinical and Laboratory Features of Acute Porphyria: A Study of 36 Subjects in a Chinese Tertiary Referral Center
BioMed Research International Volume 2016, Article ID 3927635, 5 pages http://dx.doi.org/10.1155/2016/3927635 Research Article Clinical and Laboratory Features of Acute Porphyria: A Study of 36 Subjects
More informationAcute porphyrias : Diagnosis, complications and treatment options
Porphyrins & Porphyrias / Patients Day Lucerne, May 18 th, 2013 Acute porphyrias : Diagnosis, complications and treatment options Pr Jean-Charles Deybach, MD, PhD Centre National Maladies Rares Porphyries
More informationPresentations associated with porphyrias in intensive care units
ICU ROUNDS Presentations associated with porphyrias in intensive care units Doungporn Ruthirago MD, Parunyou Julayanont MD, Supannee Rassameehiran MD ABSTRACT Porphyrias are a group of uncommon congenital
More informationResearch Institute, NC, USA. Journal of Exploratory Research in Pharmacology 2017 vol
Review Article Pathophysiology, Pharmacology and Treatment of Acute Intermittent Porphyria: A Patient Case Description and Recommendations from the Current Literature Teminioluwa Ajayi 1, Rachael Ward
More informationFamily evaluations in acute intermittent porphyria using red cell uroporphyrinogen I synthetasel
Journal of Medical Genetics, 1979, 16, 134-139 Family evaluations in acute intermittent porphyria using red cell uroporphyrinogen I synthetasel JOEL M. LAMON, BRUCE C. FRYKHOLM, AND DONALD P. TCHUDY From
More informationAs befits a hematologic class of disorders, the word
Clinical Case Conference Acute Porphyrias: A Case Report and Review Heydy L. González-Arriaza, M.D. J. Michael Bostwick, M.D. As befits a hematologic class of disorders, the word porphyria derives from
More informationThere are four types of acute porphyrias:
www.thinkporphyria.com.au Acute porphyrias manifest as intermittent clinical presentations known as the acute porphyria attack. Failure to recognise an acute attack may lead to complications, and in some
More informationCommuniqué. The Challenges of Testing For and Diagnosing Porphyrias
Communiqué November 2002 AVolume 27 Number 11 Features The Challenges of Testing For and Diagnosing Porphyrias Inside Ask Us Abstracts of Interest Calendar Test Updates: Cobalt Serum Specimen Correction
More informationOpen-Label Study of Hemin for Acute Porphyria: Clinical Practice Implications
The American Journal of Medicine (2006) 119, 801.e19-801.e24 CLINICAL RESEARCH STUDY AJM Theme Issue: GI and Nutrition Open-Label Study of Hemin for Acute Porphyria: Clinical Practice Implications Karl
More informationWhen mixed as directed with Sterile Water for Injection, USP, each 48 ml provides the equivalent of approximately 336 mg hematin (7 mg/ml).
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PANHEMATIN safely and effectively. See full prescribing information for PANHEMATIN. PANHEMATIN (hemin
More informationFatal Neurological Manifestations of Acute Intermittent Porphyria
Bahrain Medical Bulletin, Vol.26, No. 2, June 2004 Fatal Neurological Manifestations of Acute Intermittent Porphyria Adel A Al Jishi, FRCPI* Sreekantaswamy, MD, DM(Neurology)** Three patients of acute
More informationINTERMEDIARY METABOLISM
INTERMEDIARY METABOLISM Porphyrin Metabolism Dr Puneet Kumar Nigam M-117, Greater Kailash Part II New Delhi 110048 31 Mar 2007 (Revised 15 Oct 2007) CONTENTS Porphyrins Porphyrias Erythropoietic Porphyrias
More informationENZYMES OF HEME METABOLISM IN THE KIDNEY Regulation by Trace Metals Which Do Not Form Heme Complexes*
Published Online: 1 November, 1977 Supp Info: http://doi.org/10.1084/jem.146.5.1286 Downloaded from jem.rupress.org on October 2, 2018 ENZYMES OF HEME METABOLISM IN THE KIDNEY Regulation by Trace Metals
More informationREVIEWS. Clinical, Biochemical and Molecular Characteristics of the Main Types of Porphyria. Heme Biosynthesis
REVIEWS Adv Clin Exp Med 2016, 25, 2, 361 368 DOI: 10.17219/acem/58955 Copyright by Wroclaw Medical University ISSN 1899 5276 Urszula Szlendak 1, 2, D F, Ksenia Bykowska 2, A, D F, Agnieszka Lipniacka
More informationPorphyrias in Japan. Epidemiological Statistics of Porphyrias
Porphyrias in Japan Masao Kondo,a Yuzo Yanob "Department of Nutrition and Biochemistry, The Institute of Public Health, Tokyo, Japan; btokyo Metropolitan Toshima General Hospital, Tokyo, Japan Key Words.
More informationCitation Acta Medica Nagasakiensia. 1992, 37
NAOSITE: Nagasaki University's Ac Title Author(s) An Autopsy Case of Acute Intermitte Murase, Kunihiko; Makiyama, Kazuya; Nonaka, Shigeru Citation Acta Medica Nagasakiensia. 1992, 37 Issue Date 1992-12-25
More informationThe Atkins Diet as a Possible Trigger for an ICU Admission: A Case Report
The Atkins Diet as a Possible Trigger for an ICU Admission: A Case Report J. F. FRASER, P. LONGDEN Intensive Care Unit, St Andrew s Hospital, Toowoomba, QUEENSLAND ABSTRACT A case of initial presentation
More informationDosing, preparation, and infusion instructions
Dosing, preparation, and infusion instructions About PANHEMATIN PANHEMATIN is supplied as a sterile, lyophilized, black powder in single-dose dispensing vials containing 350 mg hemin, 240 mg sodium carbonate,
More informationMetabolism of porphyrins and bile pigments. Mária Sasvári 2017
Metabolism of porphyrins and bile pigments Mária Sasvári 2017 1 The biological role of porphyrins rotoporphyrin IX + Fe 2+ heme the prosthetic group of several proteins, such as: hemoglobin, myoglobin
More informationINSIDER S GUIDE Urinary porphyrin profiling
Functional Medicine University s Functional Diagnostic Medicine Training Program INSIDER S GUIDE Urinary porphyrin profiling By Ron Grisanti, D.C. & Dicken Weatherby, N.D. http://www.functionalmedicineuniversity.com
More informationCase Report Feigning Acute Intermittent Porphyria
Case Reports in Psychiatry, Article ID 152821, 4 pages http://dx.doi.org/10.1155/2014/152821 Case Report Feigning Acute Intermittent Porphyria Rania Elkhatib, 1 Modupe Idowu, 2 Gregory S. Brown, 3 Yasmeen
More informationPII S (99) Biochemical Differentiation of the Porphyrias
PII S0009-9120(99)00067-3 Clinical Biochemistry, Vol. 32, No. 8, 609 619, 1999 Copyright 1999 The Canadian Society of Clinical Chemists Printed in the USA. All rights reserved 0009-9120/99/$ see front
More informationPorphyria Cutanea Tarda as the Most Common Porphyria
2007;15(4):254-263 REVIEW Porphyria Cutanea Tarda as the Most Common Porphyria Vedrana Bulat, Liborija Lugović, Mirna Šitum, Marija Buljan, Lada Bradić 1 University Department of Dermatology and Venereology,
More informationCutaneous Deposition Disorders
Cutaneous Deposition Disorders Group of unrelated conditions characterized by the presence of endogenous or exogenous substances within the dermis or subcutis Endogenous Cutaneous Deposition Disorders
More informationUpdate review of the acute porphyrias
review Update review of the acute porphyrias Penelope E. Stein, 1 Michael N. Badminton 2 and David C. Rees 1 1 Department of Haematological Medicine, King s College Hospital, London, and 2 Department of
More informationComposition of Urinary Coproporphyrin Isomers I IV in Human Porphyrias 1 )
Jacob and Doss: Coproporphyrin isomers in s 67 Eur. J. Clin. Chem. Clin. Biochem. Vol. 3, 993, pp. 67-624 993 Walter de Gruyter & Co. Berlin New York Composition of Urinary Coproporphyrin Isomers I IV
More informationHeme Biosynthesis and Porphyrin Studies in Chronic Renal Failure Patients Following Kidney Transplantation
International Uroloyy and Nephroloyy 23 (5), pp. 503--509 (1991) Heme Biosynthesis and Porphyrin Studies in Chronic Renal Failure Patients Following Kidney Transplantation M. EL-FAR,* M. SOBH,** M. GHONIEM,**
More informationDr. M. Fathima Riswana IIyrMD MII & Hematology Dept, ICH & HC Prof.Dr.S.Sundari Prof.Dr.V.Thilagavathy
Dr. M. Fathima Riswana IIyrMD MII & Hematology Dept, ICH & HC Prof.Dr.S.Sundari Prof.Dr.V.Thilagavathy History 1yr old male child, 1st born of 3rd degree consanguineous marriage with c/o abdominal distension
More informationAmino Acid Metabolism: Conversion of Amino Acids to Specialized Products
Amino Acid Metabolism: Conversion of Amino Acids to Specialized Products Dr. Diala Abu-Hassan, DDS, PhD Medical students-first semester All images are taken from Lippincott s Biochemistry textbook except
More informationCHAPTER 27. Haem biosynthesis and the porphyrias. Jean-Charles Deybach, Laurent Gouya, Hervé Puy
IRO2009_CAP.27(624-641):EBMT2008 4-12-2009 16:46 Pagina 624 * CAPTER 27 aem biosynthesis and the porphyrias Jean-Charles Deybach, Laurent Gouya, ervé Puy IRO2009_CAP.27(624-641):EBMT2008 4-12-2009 16:46
More informationNormosang. Human hemin. Normosang Product Monograph 1 of 59
Normosang Human hemin Normosang Product Monograph 1 of 59 ABBREVIATIONS AD ADP AIP ALA ALAD AR C (O) C (max) CAS COPRO CPO CYP EPNET FECH FRCBS Haem-S HCP HO INN MDS NaCl PBG PBGD PPOX PROTO PT PTT qs
More informationCase Challenges in Acute Intermittent Porphyria CME
Case Challenges in Acute Intermittent Porphyria CME Supported by an independent educational grant from Recordati Rare Diseases 1 This article is a CME activity. To earn credit for this activity visit:
More informationPorphyria in Japan : The Past, Present, and Future
Porphyrins 009: 8(-3),-6 Mini Review Porphyria in Japan : The Past, Present, and Future Masao KONDO ) and Tetsuya KUBO,3) ) Faculty of Human Life Sciences, Musashi Institute of Technology, 8-9-8, Todoroki,
More informationAmino acid oxidation and the production of urea
Seminar 10 Urea cycle Amino acid oxidation and the production of urea Oxidation Waste or Reuse Ammonia has to be eliminated ammonia originates in the catabolism of amino acids that are primarily produced
More informationAfamelanotide for erythropoietic protoporphyria and congenital erythropoietic porphyria
Afamelanotide for erythropoietic protoporphyria and congenital erythropoietic porphyria This technology summary is based on information available at the time of research and a limited literature search.
More informationPharmacokinetics of intravenously administered haem arginate
Br. J. clin. Pharmac. (1986), 22, 331-335 Pharmacokinetics of intravenously administered haem arginate OLAVI TOKOLA1, RAIMO TENHUNEN2, LIISA VOLIN3 & PERTrI MUSTAJOKI3 'Research Laboratories of Huhtamaki
More informationAcute Intermittent Porphyria: Psychosis as the Only Clinical Manifestation
Isr J Psychiatry Relat Sci Vol 43 No. 1 (2006) 52 56 Acute Intermittent Porphyria: Psychosis as the Only Clinical Manifestation Natalie Ellencweig, MD, 1 Nili Schoenfeld, PhD, 2,3 and Zvi Zemishlany, MD
More informationI coproporphyrinogen oxidase. Hereditary coproporphyria and epilepsy. I protoporphyrinogen oxidos.
Archives of Disease in Childhood, 1977, 52, 646-650 Hereditary coproporphyria and epilepsy A. B. HOUSTON, M. J. BRODE, M. R. MOORE, G. G. THOMPSON, AND J. B. P. STEPHENSON From the Royal Hospitalfor Sick
More informationAmino Acid Metabolism: Conversion of Amino Acids to Specialized Products
Amino Acid Metabolism: Conversion of Amino Acids to Specialized Products Dr. Diala Abu-Hassan, DDS, PhD Medical students-first semester All images are taken from Lippincott s Biochemistry textbook except
More informationNeurological manifestations and molecular genetics of acute intermittent porphyria in North Western Russia
Research Program in Molecular Medicine, Biomedicum-Helsinki, Department of Medicine University of Helsinki, Finland Neurological manifestations and molecular genetics of acute intermittent porphyria in
More informationdisorder The little imitator-porphyria: a neuropsychiatric REVIEW plants. The description of the porphyrins by
Journal of Neurology, Neurosurgery, and Psychiatry 1997;62:319-328 319 REVIEW Department of Neuropsychiatry, Institute of Neurology, Queen Square, London, UK H L Crimnlisk Address for correspondence: Dr
More informationScreening Tests for Porphobilinogen Are Insensitive
Screening Tests for Porphobilinogen Are Insensitive The Problem and Its Solution WILLIAM E. SCHREIBER, M.D., AZIM JAMANI, R.T., AND MORRIS R. PUDEK, PH.D. Standard screening tests for porphobilinogen (PBG)
More informationOpen Research Online The Open University s repository of research publications and other research outputs
Open Research Online The Open University s repository of research publications and other research outputs Porphyrin metabolism in congenital erythropoietic porphyria Thesis How to cite: Guo, Rong (1992).
More informationGoodridge - Heme Synthesis
Goodridge - Heme Synthesis Study online at quizlet.com/_8r779 1. Acquired Porphyrias (lead poisoning) -inactivates ALA DHD -ALA appears in urine -inhibits protoporphyrinogen oxidase -free protoporphyrinogen
More informationPORPHYRIN COMPLEXATION: AN APPROACH IN PORPHYRIA THERAPY. Bolanle C. AKINWUMI
PORPHYRIN COMPLEXATION: AN APPROACH IN PORPHYRIA THERAPY By Bolanle C. AKINWUMI A thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements
More informationErythrocyte Uroporphyrinogen I Synthase Activity as an Indicator of Acute Porphyria
A N N A L S O F C L IN IC A L A N D L A B O R A T O R Y S C IE N C E, Vol. 19, N o. 2 Copyright 1989, Institute for Clinical Science, Inc. Erythrocyte Uroporphyrinogen I Synthase Activity as an Indicator
More informationThe citric acid cycle
Integration of metabolism pathways Mitochondria The citric acid cycle Biosynthesis of haem Biochemistry I Lecture 10 2008 (J.S.) Stages in the extraction of energy from foodstuffs The first stage of catabolism
More informationMolecular pathology of porphyrias
Molecular pathology of porphyrias MUDr. Eva Flachsová 1st Faculty of Medicine Charles University Prague, Czech Republic PhD thesis Biochemistry and Pathobiochemistry Prague 2007 This PhD thesis was elaborated
More informationMolecular and Biochemical Studies of Acute Intermittent Porphyria in 196 Patients and Their Families
Clinical Chemistry 48:11 1891 1900 (2002) Molecular Diagnostics and Genetics Molecular and Biochemical Studies of Acute Intermittent Porphyria in 196 Patients and Their Families Raili Kauppinen * and Mikael
More informationLATE ACUTE INTERMITTENT PORPHYRIA ATTACK IN A PATIENT WITH TYPE 2 DIABETES
2015 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 22(2):125-131 doi: 10.1515/rjdnmd-2015-0016 LATE ACUTE INTERMITTENT PORPHYRIA ATTACK IN A PATIENT WITH
More informationDiagnosis? What s Your. Why is my skin so fragile? What s your diagnosis? In this article: By Elizabeth Satter MD; and Catherine Maari, MD, FRCPC
What s Your Diagnosis? Why is my skin so fragile? By Elizabeth Satter MD; and Catherine Maari, MD, FRCPC Mr. Young, a 67-year-old homeless male, was admitted to the hospital for a course of intravenous
More informationPapers in Press. First published February 19, 2004 as doi: /clinchem
Papers in Press. First published February 19, 2004 as doi:10.1373/clinchem.2003.025213 Clinical Chemistry 50:5 000 000 (2004) General Clinical Chemistry Plasma Fluorescence Scanning and Fecal Porphyrin
More informationHereditary coproporphyria: incidence in a large
Journal of Medical Genetics, 1984, 21, 341-349 Hereditary coproporphyria: incidence in a large English family * J ANDREWSt, H ERDJUMENT+, AND D C NICHOLSON+ From the tdepartment of Geriatric Medicine,
More information2013 OTS Annual Meeting Pre-clinical Development of ALN-AS1 RNAi Therapeutic for the Treatment of Acute Intermittent Porphyria.
2013 OTS Annual Meeting Pre-clinical Development of ALN-AS1 RNAi Therapeutic for the Treatment of Acute Intermittent Porphyria October 8, 2013 Acute Intermittent Porphyria (AIP) Program Unmet Need and
More informationPorphyria in Switzerland, 15 years experience
Original article Peer reviewed article SWISS MED WKLY 2009;139(13 14):198 206 www.smw.ch 198 Porphyria in Switzerl, 15 years experience Xiaoye Schneider-Yin, Juergen Harms, Elisabeth I. Minder Central
More informationDivision of Preventive and Social Medicine, Department of Hygiene and Public Health Osaka Medical College, Takatsuki-city, Osaka , Japan
Long-Term Follow-up of Erythrocyte Porphobilinogen Deaminase Activity in a Patient With Acute Intermittent Porphyria: The Relationship between the Enzyme Activity and Abdominal Pain
More informationTreatment with Haematin in Acute Hepatic Porphyria
Quarterly Journal of edicine, New Series L, No. 198, pp. 161-17, Spring 1981 Treatment with Haematin in Acute Hepatic Porphyria K. E. L. ccqll,. R. OORE, G. G. THOPSON AND A. GOLDBERG rom the University
More informationHematopoiesis, The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid.
Hematopoiesis, 200 billion new blood cells per day The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid. hematopoietic growth factors, proteins that regulate the proliferation
More informationINTRODUCTION. Chapter. Overview. Li Zhang
Chapter 1 INTRODUCTION Li Zhang Overview Heme, iron protoporphyrin IX (Fig. 1), is arguably one of life s most central molecules. Most of us know about heme because of hemoglobin the molecule that transports
More informationDOWNLOAD PDF HAEM, BILIRUBIN AND PORPHYRIES
Chapter 1 : HPU website - english version - What's HPU? The Porphyrin and Heme Synthesis and Bilirubin Metabolism page describes the processes of heme synthesis and degradation as well as descriptions
More informationThe porphyrias: a review
The porphyrias: a review G. H. ELDER, C. H. GRAY, AND D. C. NICHOLSON J. clin. Path., 1972, 25, 1013-1033 From the Department of Chemical Pathology, King's College Hospital Medical School, Denmark Hill,
More informationThe cutaneous porphyrias: a review
British Journal of Dermatology 1999; 140: 573 581. The cutaneous porphyrias: a review G.M.MURPHY, FOR THE BRITISH PHOTODERMATOLOGY GROUP Photobiology Unit, Beaumont and Mater Misericordiae Hospitals, Dublin
More informationKey words: Right ventricular heart failure, Uroporphyrin, Coproporphyrin, Protoporphyrin.
Porphyria Cutanea Tarda with Constrictive Pericarditis in a Family Susumu ADACHI,1 MD, Jun AMANO,2 MD, Hiroshi ITO,1 MD, Takashi YAJIMA,3 MD, Toshizumi SHIRAI,2 MD, Yasuhiro MIYAHARA,3 MD, Fumiaki MARUMO,1
More informationPorphyrias An Overview and Update for Physicians and their Staffs
Authors: Brandon Marion, MD Jared Rejeski, MD Sean Rudnick, MD Herbert L. Bonkovsky, MD Affiliation: Section on Gastroenterology and Hepatology, Department of Internal Medicine, Wake Forest University
More informationUrea is the major end product of nitrogen catabolism in humans One nitrogen free NH3 other nitrogen aspartate. carbon oxygen CO2 liver,
Urea is the major end product of nitrogen catabolism in humans Urea is the major disposal form of amino groups derived from amino acids, and accounts about 90% percent of the nitrogencontaining components
More informationGivosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Rose Living with Porphyria Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias Thursday, September 7, 2017 Agenda Welcome Josh Brodsky, Associate Director, Investor
More informationClinical Issues in AIP: When to Suspect and How to Proceed CME/CE
Clinical Issues in AIP: When to Suspect and How to Proceed CME/CE Supported by an independent educational grant from Recordati Rare Diseases. Clinical Issues in AIP: When to Suspect and How to Proceed
More informationPorphyria DNA Testing Laboratory Established by the APF
1st Quarter, 2006 Porphyria DNA Testing Laboratory Established by the APF A year ago, an anonymous APF member, recognizing the importance of gene testing for the seven porphyrias, provided a grant to the
More informationClinical and biochemical characteristics and genotype phenotype correlation in Finnish variegate porphyria patients
(2002) 10, 649 657 ª 2002 Nature Publishing Group All rights reserved 1018 4813/02 $25.00 www.nature.com/ejhg ARTICLE Clinical and biochemical characteristics and genotype phenotype correlation in Finnish
More informationSAFE USE OF PERAMPANEL IN A CARRIER OF VARIEGATE PORPHYRIA: A CASE REPORT
SAFE USE OF PERAMPANEL IN A CARRIER OF VARIEGATE PORPHYRIA: A CASE REPORT S Balestrini 1-2, Y Hart 3, S Thunell 4, SM Sisodiya 1 1 NIHR University College London Hospitals Biomedical Research Centre, Department
More informationThe prinicipal sites of heme biosynthesis are liver
REVIEW Liver Transplantation in the Management of Porphyria Ashwani K. Singal, 1 Charles Parker, 2 Christine Bowden, 3 Manish Thapar, 4 Lawrence Liu, 5 and Brendan M. McGuire 1 Porphyrias are a group of
More informationRepression of the Overproduction of Porphyrin Precursors in Acute
Proc. Nat. Acad. Sci. USA Vol. 68, No. 11, pp. 2725-2729, November 1971 Repression of the Overproduction of Porphyrin Precursors in Acute Intermittent Porphyria by Intravenous Infusions of Hematin (6-aminolevulinic
More information26 June 2017 I ICPP I Bordeaux, France. Colin Living with Porphyria
Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Givosiran (ALN-AS1), an Investigational RNAi Therapeutic, for the Treatment of Acute Hepatic Porphyrias Colin Living with Porphyria
More information26 June 2017 I ICPP I Bordeaux, France. Colin Living with Porphyria
Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Givosiran (ALN-AS1), an Investigational RNAi Therapeutic, for the Treatment of Acute Hepatic Porphyrias Colin Living with Porphyria
More informationOmar Jabaiti+Saif Yamin
34 Saif Yamin + Omar Jabaiti Omar Jabaiti+Saif Yamin ABDALLAH FAHMAWI DIALA NOTE : ask OMAR about the first 5 pages and SAIF about last 5 Phenylketonuria: (PKU) Amino Acid Metabolism Disorders Phenylketonuria
More informationThe porphyrias: advances in diagnosis and treatment
Review article The porphyrias: advances in diagnosis and treatment Manisha Balwani 1 and Robert J. Desnick 1 1 Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY
More informationLast time we finished the abnormal hemoglobins. We have some hemoglobin. 5 Abdel-muez siyam Abdullah nimer Dr. nayef. Page 1
Last time we finished the abnormal hemoglobins. We have some hemoglobin 5 Abdel-muez siyam Abdullah nimer Dr. nayef Page 1 derivatives (mostly outside the book) that are of importance: 1. Normal derivatives:
More informationAcute Intermittent Porphyria : Management Aspects
POSTGRADUATE CLINIC JIACM 2002; 3(3): 252-7 Acute Intermittent Porphyria : Management Aspects Rajashekar Reddi*, Nitin K Sethi**, Ish Anand***, PK Sethi**** Abstract Porphyrias are multifactorial genetic
More informationCase Report Acute Intermittent Porphyria Associated with Respiratory Failure: A Multidisciplinary Approach
Critical Care Research and Practice Volume 2011, Article ID 283690, 4 pages doi:10.1155/2011/283690 Case Report Acute Intermittent Porphyria Associated with Respiratory Failure: A Multidisciplinary Approach
More informationDrug treatment in acute porphyria
Br J Clin Pharmacol 1997; 44: 427 434 Drug treatment in acute porphyria A. Gorchein Department of Clinical Pharmacology and Therapeutics, Imperial College School of Medicine at St Mary s, Queen Elizabeth
More informationAcute Hepatic Porphyrias: Recommendations for Evaluation and Long Term., Bruce Wang MD 2, Karl E. Anderson, MD 3, Joseph R.
Acute Hepatic Porphyrias: Recommendations for Evaluation and Long Term Management Concise Review Manisha Balwani, MD, MS 1, Bruce Wang MD 2, Karl E. Anderson, MD 3, Joseph R. Bloomer, MD 4, D. Montgomery
More information